Download integrale PDF - Progetto Mondiale Asma - Ginasma

122. Busse WW, Chervinsky P, Condemi J, Lumry WR, Petty
TL, Rennard S, et al. Budesonide delivered by
Turbuhaler is effective in a dose-dependent fashion
when used in the treatment of adult patients with chronic
asthma [published erratum appears in J Allergy Clin
Immunol 1998; 102: 511].
J Allergy Clin Immunol 1998; 101: 457-63.
123. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE,
O’Byrne P, Barnes PJ, et al. Effect of inhaled formoterol
and budesonide on exacerbations of asthma. Formoterol
and Corticosteroids Establishing Therapy (FACET)
International Study Group.
N Engl J Med 1997; 337: 1405-11.
124. Sont JK, Willems LN, Bel EH, van Krieken JH,
Vandenbroucke JP, Sterk PJ. Clinical control and
histopathologic outcome of asthma when using airway
hyperresponsiveness as an additional guide to long-term
treatment. The AMPUL Study Group.
Am J Respir Crit Care Med. 1999 Apr;
159(4 Pt 1): 1043-51
125. Green RH, Brightling CE, McKenna S, Hargadon B,
Parker D, Bradding P, Wardlaw AJ, Pavord ID. Asthma
exacerbations and sputum eosinophil counts: a
randomised controlled trial. Lancet. 2002; 360: 1715-1721
126. Mash B, Bheekie A, Jones PW. Inhaled vs oral steroids
for adults with chronic asthma.
Cochrane Database Syst Rev 2000; 2.
127. Toogood JH, Baskerville J, Jennings B, Lefcoe NM,
Johansson SA. Bioequivalent doses of budesonide and
prednisone in moderate and severe asthma.
J Allergy Clin Immunol 1989; 84: 688-700.
128. Williamson IJ, Matusiewicz SP, Brown PH, Greening AP,
Crompton GK. Frequency of voice problems and cough
in patients using pressurized aerosol inhaled steroid
preparations. Eur Respir J 1995; 8: 590-2.
129. Lipworth BJ. Systemic adverse effects of inhaled
corticosteroid therapy: A systematic review and
metaanalysis.
Arch Intern Med 1999; 159: 941-55.
130. Kamada AK, Szefler SJ, Martin RJ, Boushey HA,
Chinchilli VM, Drazen JM, et al. Issues in the use of
inhaled glucocorticoids. The Asthma Clinical Research
Network. Am J Respir Crit Care Med 1996; 153: 1739-48.
131. Selroos O, Halme M. Effect of a volumatic spacer and
mouth rinsing on systemic absorption of inhaled
corticosteroids from a metered dose inhaler and dry
powder inhaler. Thorax 1991; 46: 891-4.
132. Mak VH, Melchor R, Spiro SG. Easy bruising as a sideeffect
of inhaled corticosteroids.
Eur Respir J 1992; 5: 1068-74.
133. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP,
Postma DS, Pride NB, et al. Long-term treatment with
inhaled budesonide in persons with mild chronic
obstructive pulmonary disease who continue smoking.
European Respiratory Society Study on Chronic
Obstructive Pulmonary Disease.
N Engl J Med 1999; 340: 1948-53.
134. Effect of inhaled triamcinolone on the decline in
pulmonary function in chronic obstructive pulmonary
disease. N Engl J Med 2000; 343: 1902-9.
135. Pauwels RA, Yernault JC, Demedts MG, Geusens P.
Safety and efficacy of fluticasone and beclomethasone
in moderate to severe asthma. Belgian Multicenter Study
Group. Am J Respir Crit Care Med 1998; 157: 827-32.
136. Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and
nasal glucocorticoids and the risks of ocular
hypertension or open-angle glaucoma.
JAMA 1997; 277: 722-7.
137. Cumming RG, Mitchell P, Leeder SR. Use of inhaled
corticosteroids and the risk of cataracts.
N Engl J Med 1997; 337: 8-14.
138. Agertoft L, Larsen FE, Pedersen S. Posterior
subcapsular cataracts, bruises and hoarseness in
children with asthma receiving long-term treatment with
inhaled budesonide. Eur Respir J 1998; 12: 130-5.
139. Toogood JH, Markov AE, Baskerville J, Dyson C.
Association of ocular cataracts with inhaled and oral
steroid therapy during long-term treatment of asthma.
J Allergy Clin Immunol 1993; 91: 571-9.
140. Simons FE, Persaud MP, Gillespie CA, Cheang M,
Shuckett EP. Absence of posterior subcapsular cataracts
in young patients treated with inhaled glucocorticoids.
Lancet 1993; 342: 776-8.
141. Dunlap NE, Fulmer JD. Corticosteroid therapy in
asthma. Clin Chest Med 1984; 5: 669-83.
142. Recommendations for the prevention and treatment of
glucocorticoid-induced osteoporosis. American College
of Rheumatology Task Force on Osteoporosis
Guidelines.
Arthritis Rheum 1996; 39: 1791-801.
143. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I,
Francis RM, et al. A UK Consensus Group on
management of glucocorticoid-induced osteoporosis: an
update. J Intern Med 1998; 244: 271-92.
144. Health advisory for new asthma drug. Food and Drug
Administration, US Department of Health and Human
Services, 1998. Available from http:
//www.fda.gov/bbs/topics/ANSWERS/ANS00810.
html.
PROGRAMMA DI TRATTAMENTO DELL’ASMA IN SEI PARTI 159